Emergent BioSolutions Inc. has recently been awarded over $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS). The company will be supplying millions of doses of four critical medical countermeasure products to the U.S. government.

One of the contract modifications, valued at $30.0 million, is for the supply of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) this year. CYFENDUS, previously known as AV7909, is a two-dose anthrax vaccine for post-exposure prophylaxis in individuals 18 years of age and older. This funding comes from Emergent’s existing 10-year contract with the Biomedical Advanced Research and Development Authority (BARDA).

Another contract modification, valued at $99.9 million, is for the supply of ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) this year. ACAM2000 is licensed for active immunization against smallpox disease for individuals at high risk of infection. This falls under Emergent’s existing 10-year contract with ASPR.

Additionally, two new contract options totaling $122.9 million have been awarded to supply the Strategic National Stockpile with VIGIV [Vaccinia Immune Globulin Intravenous (Human)] drug product and BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] drug substance. These contracts involve the delivery of drug production this year and into early 2025. VIGIV is used for the treatment of complications to smallpox vaccination, while BAT is indicated for the treatment of symptomatic botulism following exposure to botulinum neurotoxin serotypes in adults and pediatric patients.

Emergent BioSolutions Inc. expressed that securing these contract modifications with the U.S. government affirms the company as a trusted biodefense partner and highlights the strength and sustainability of their product portfolio.